<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58332">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02346643</url>
  </required_header>
  <id_info>
    <org_study_id>11-SMI-2013</org_study_id>
    <nct_id>NCT02346643</nct_id>
  </id_info>
  <brief_title>A Post Market Evaluation of Chronic intractaBle paIN and the Efficacy of drG stimulatiOn in the Nordic Region</brief_title>
  <acronym>BINGO</acronym>
  <official_title>BINGO: A Post Market Evaluation of Chronic intractaBle paIN and the Efficacy of drG stimulatiOn in the Nordic Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      11-SMI-2013 is a post market, observational, questionnaire based study to assess the
      effectiveness of the commercially available Axium neurostimulator in the management of
      intractable, chronic pain
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Budget Allocation Decision by Sponsor
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief - Assessed by Change in Pain Intensity on a Visual Analogue Scale (VAS) from Pre-Treatment Baseline</measure>
    <time_frame>Post treatment at; 1 week and 1, 3, 6, 12 and 24 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Treated Subjects</arm_group_label>
    <description>All subjects recruited and treated with the Axium neurostimulator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation with the commercially available Axium Neurostimulator</intervention_name>
    <arm_group_label>Treated Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Pain Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is at least 18 years old

          2. Subject is able and willing to comply with the follow-up schedule and protocol

          3. Chronic, intractable pain for at least 6 months

          4. Failed conservative treatments for chronic pain including but not limited to
             pharmacological therapy, physical therapy and interventional pain procedures for
             chronic pain

          5. Minimum baseline pain rating of 60 mm on the VAS in the primary region of pain

          6. Subject is able to provide written informed consent

        Exclusion Criteria:

          1. Female subject of childbearing potential is pregnant/nursing or plans to become
             pregnant during the study duration

          2. Escalating or changing pain condition within the past month as evidenced by
             investigator examination

          3. Subject has had corticosteroid therapy at an intended site of stimulation within the
             past 30 days

          4. Subject has had radiofrequency treatment of an intended target DRG within the past 3
             months

          5. Subject currently has an active implantable device including ICD, pacemaker, spinal
             cord stimulator or intrathecal drug pump

          6. Subject is unable to operate the device

          7. Subjects currently has an active infection

          8. Subject has participated in another clinical investigation within 30 days

          9. Subject has a coagulation disorder or uses anticoagulants that, in the opinion of the
             investigator, precludes participation

         10. Subject has been diagnosed with cancer in the past 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Akademiska sjukhuest</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 15, 2015</lastchanged_date>
  <firstreceived_date>January 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Pain, Intractable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
